Reviewing Ovid Therapeutics (OVID) and Its Competitors

Ovid Therapeutics (NASDAQ:OVID – Get Free Report) is one of 894 public companies in the “Pharmaceuticals” industry, but how does it compare to its rivals? We will compare Ovid Therapeutics to similar businesses based on the strength of its valuation, profitability, institutional ownership, dividends, earnings, analyst recommendations and risk.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Ovid Therapeutics and its rivals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ovid Therapeutics 1 0 11 0 2.83
Ovid Therapeutics Competitors 7866 13816 25856 1042 2.41

Ovid Therapeutics presently has a consensus target price of $6.12, indicating a potential upside of 177.78%. As a group, “Pharmaceuticals” companies have a potential upside of 30.31%. Given Ovid Therapeutics’ stronger consensus rating and higher possible upside, equities analysts plainly believe Ovid Therapeutics is more favorable than its rivals.

Valuation & Earnings

This table compares Ovid Therapeutics and its rivals revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Ovid Therapeutics $7.25 million -$17.41 million -9.19
Ovid Therapeutics Competitors $3.54 billion $3.17 billion 556.78

Ovid Therapeutics’ rivals have higher revenue and earnings than Ovid Therapeutics. Ovid Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Institutional and Insider Ownership

72.2% of Ovid Therapeutics shares are held by institutional investors. Comparatively, 32.5% of shares of all “Pharmaceuticals” companies are held by institutional investors. 7.0% of Ovid Therapeutics shares are held by company insiders. Comparatively, 14.1% of shares of all “Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Volatility and Risk

Ovid Therapeutics has a beta of 0.24, meaning that its share price is 76% less volatile than the S&P 500. Comparatively, Ovid Therapeutics’ rivals have a beta of -0.05, meaning that their average share price is 105% less volatile than the S&P 500.

Profitability

This table compares Ovid Therapeutics and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Ovid Therapeutics N/A -23.38% -20.76%
Ovid Therapeutics Competitors -2,391.71% -206.07% -14.88%

Summary

Ovid Therapeutics beats its rivals on 7 of the 12 factors compared.

About Ovid Therapeutics

(Get Free Report)

Ovid Therapeutics Inc. is a biopharmaceutical company focused on developing medicines for epilepsies and other neurological disorders. Its work targets conditions with significant unmet treatment needs, including rare and difficult-to-treat seizure disorders. The company’s lead development program, OV329, is an investigational GABA aminotransferase inhibitor being studied as a potential treatment for seizures, including infantile spasms and focal-onset seizures. Ovid’s pipeline and research programs may change as clinical development progresses.

Receive News & Ratings for Ovid Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ovid Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.